|
Circulating tumor DNA profiling to identify patients with metastatic colorectal cancer with improved overall survival following Sym004 treatment. |
|
|
Employment - Synaptive Medical |
Stock and Other Ownership Interests - Synaptive Medical |
Patents, Royalties, Other Intellectual Property - Synaptive Medical |
|
|
Employment - Synaptive Medical |
Stock and Other Ownership Interests - Symphony Evolution |
Patents, Royalties, Other Intellectual Property - Synaptive Medical |
|
|
Employment - Symphony Evolution |
Stock and Other Ownership Interests - Synaptive Medical |
|
|
Employment - Synaptive Medical |
Stock and Other Ownership Interests - Synaptive Medical |
Patents, Royalties, Other Intellectual Property - Synaptive Medical |
|
|
Employment - Synaptive Medical |
Patents, Royalties, Other Intellectual Property - Synaptive Medical |
|
|
Employment - Synaptive Medical |
|
|
Consulting or Advisory Role - Astellas Pharma; Novartis; Roche/Genentech |
|
|
|
No Relationships to Disclose |
|
|
Employment - Synaptive Medical |
Stock and Other Ownership Interests - Synaptive Medical |
|
|
Stock and Other Ownership Interests - MolecularMatch; Navire |
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; EMD Serono; Genentech; Guardant Health (Inst); Karyopharm Therapeutics; Merck; Roche; Symphony Evolution |
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Genentech/Roche; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical |